Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7019111 | 0.93 | NPSR1 (0.37) | DGAT1NPSR1 | |
| SCHEMBL16067775 | 0.93 | NPSR1 (0.33) | DGAT1NPSR1 | |
| SCHEMBL28751471 | 0.92 | NPSR1 (0.36) | DGAT1NPSR1 | |
| SCHEMBL15218842 | 0.90 | CTSD (0.36) | DGAT1CTSDCTSLCTSBCTSS | |
| SCHEMBL24629871 | 0.86 | USP2 (0.34) | DGAT1CTSDCTSLCTSBCTSS | |
| SCHEMBL15218843 | 0.84 | USP2 (0.34) | CTSDCTSLCTSBCTSSASGR1 | |
| SCHEMBL27032861 | 0.83 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL6290186 | 0.83 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL1771222 | 0.81 | FABP4 (0.35) | CTSDCTSLCTSBCTSSASGR1 | |
| SCHEMBL15116516 | 0.81 | CTSD (0.32) | CTSDCTSLCTSBCTSSASGR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023225005-A1 | FLT3 COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220363686-A1 | NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220227789-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-07-21 | — | — | US | disclosed |
| US-20220227785-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-07-21 | — | — | US | disclosed |
| EP-3962912-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962913-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962914-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20140212381-A1 | MACROCYCLES | SCYNEXIS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140212381-A1 | MACROCYCLES | SCYNEXIS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014063147-A1 | NEW ANTIVIRAL MACROCYCLES | SCYNEXIS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014063147-A1 | NEW ANTIVIRAL MACROCYCLES | SCYNEXIS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| WO-2012019430-A1 | PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | disclosed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | disclosed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227789-A1 | NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | DGAT1 4283/4885NPSR1 3909/4885CTSD 3098/4885 |
| US-20220227785-A1 | NOVEL PHENYL AND PYRIDYL UREAS ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDKN1A, CDK2 | DGAT1 4474/4885NPSR1 4057/4885CTSD 3508/4885 |
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | DGAT1 4281/4885NPSR1 92/4885CTSD 4664/4885 |
| US-20220363686-A1 | NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | DGAT1 4447/4885NPSR1 3476/4885CTSD 4060/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | DGAT1 1404/4885NPSR1 341/4885CTSD 3354/4885 |
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | HCCS, IDO1, BRD4 | DGAT1 4341/4885NPSR1 2090/4885CTSD 3291/4885 |
| US-20140212381-A1 | MACROCYCLES | HAVCR2, ICOS, FKBP14 | DGAT1 4637/4885NPSR1 3975/4885CTSD 289/4885 |
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | CHRNA1, CHRM1, CHRNA9 | DGAT1 2815/4885NPSR1 71/4885CTSD 4584/4885 |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | CHRM1, CHRM2, CHRM3 | DGAT1 3200/4885NPSR1 66/4885CTSD 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.